Thrivent Financial for Lutherans
RAPT

Thrivent Financial for Lutherans’s RAPT Therapeutics RAPT Stock Holding History

Thrivent Financial for Lutherans’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,749
Closed -$164K – 2582
2024
Q2 		$164K Buy
+6,749
New +$312K ﹤0.01% 2498
2023
Q2 		– Sell
-7,417
Closed -$1.09M – 2522
2023
Q1 		$1.09M Hold
7,417
– – ﹤0.01% 1734
2022
Q4 		$1.17M Buy
+7,417
New +$1.19M ﹤0.01% 1621

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Thrivent Financial for Lutherans's RAPT Position: Q3 2024 in Review

Thrivent Financial for Lutherans sold out of RAPT Therapeutics (RAPT) in Q3 2024, closing a stake of 6,749 shares — an estimated $164K sold.

Thrivent Financial for Lutherans first reported a position in RAPT in Q4 2022 and held it in 3 quarters. The position peaked at $1.17M in Q4 2022. 94 funds tracked by Wall St. Rank hold RAPT as of Q3 2024.

  • Thrivent Financial for Lutherans reported no remaining RAPT Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 6,749 RAPT Therapeutics shares in Q3 2024, an estimated $164K.
  • Thrivent Financial for Lutherans first reported a position in RAPT Therapeutics in Q4 2022 and held it in 3 quarters.
  • Thrivent Financial for Lutherans's RAPT Therapeutics position peaked at $1.17M in Q4 2022.
  • 94 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2024.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2024, filed 7 Nov 2024.